Lineage Cell Therapeutics (LCTX) Total Non-Current Liabilities (2010 - 2026)
Lineage Cell Therapeutics (LCTX) posted quarterly Total Non-Current Liabilities of $22.7 million for Q1 2026, down 19.04% year-over-year from $28.0 million in Q1 2025, and down 10.4% quarter-over-quarter from $25.3 million in Q4 2025.
Lineage Cell Therapeutics (LCTX) Total Non-Current Liabilities (2010 - 2026) Analysis & Trends
Lineage Cell Therapeutics' Total Non-Current Liabilities history runs 15 years deep, the most recent figure standing at $22.7 million for Q1 2026.
- In Q1 2026, Total Non-Current Liabilities fell 19.04% year-over-year to $22.7 million; the TTM figure through Mar 2026 stood at $22.7 million (down 19.04% YoY), while the FY2025 annual figure was $25.3 million, down 15.69% from the prior year.
- Total Non-Current Liabilities for Q1 2026 stood at $22.7 million, down from $25.3 million in the prior quarter.
- The five-year high for Total Non-Current Liabilities was $59.3 million in Q1 2022, with the low at $22.7 million in Q1 2026.
- The 5-year median for Total Non-Current Liabilities is $39.0 million (2023), against an average of $38.3 million.
- The sharpest annual moves came in 2022 and 2025: Total Non-Current Liabilities plunged 38.14% in 2022, then decreased 15.69% in 2025.
- Lineage Cell Therapeutics' Total Non-Current Liabilities stood at $51.7 million in 2022, then dropped by 24.61% to $39.0 million in 2023, then dropped by 22.95% to $30.0 million in 2024, then fell by 15.69% to $25.3 million in 2025, then fell by 10.4% to $22.7 million in 2026.
- Business Quant data shows LCTX's Total Non-Current Liabilities at $22.7 million in Q1 2026, $25.3 million in Q4 2025, and $23.7 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 5.92 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 7.74 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 40.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 1.53 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.88 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 9.32 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 4.20 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 1.17 Bn |
| 10 | Lineage Cell Therapeutics | 270.61 Mn | 212.77 Mn | 1.07 Mn | 21.73 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 21.73 Mn |
| Mar 31, 2026 | 22.70 Mn |
| Dec 31, 2025 | 25.33 Mn |
| Sep 30, 2025 | 23.67 Mn |
| Jun 30, 2025 | 24.89 Mn |
| Mar 31, 2025 | 28.04 Mn |
| Dec 31, 2024 | 30.05 Mn |
| Dec 31, 2023 | 39.00 Mn |
| Jun 30, 2023 | 40.43 Mn |
| Mar 31, 2023 | 44.19 Mn |
| Dec 31, 2022 | 51.73 Mn |
| Sep 30, 2022 | 53.59 Mn |
| Jun 30, 2022 | 54.42 Mn |
| Mar 31, 2022 | 59.30 Mn |
| Dec 31, 2021 | 83.62 Mn |
| Sep 30, 2018 | 6.12 Mn |
| Jun 30, 2018 | 7.10 Mn |
| Mar 31, 2018 | 7.33 Mn |
| Dec 31, 2017 | 8.18 Mn |
| Sep 30, 2017 | 12.33 Mn |